Advertisement

Topics

Latest "BioTech Capital Limited" News Stories

22:52 EDT 23rd May 2018 | BioPortfolio

Here are the most relevant search results for "BioTech Capital Limited" found in our extensive news archives from over 250 global news sources.

More Information about BioTech Capital Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioTech Capital Limited for you to read. Along with our medical data and news we also list BioTech Capital Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioTech Capital Limited Companies for you to search.

Showing "BioTech Capital Limited" News Articles 1–25 of 10,000+

Relevant

The 10 Biotech Venture Capital Firms in Europe to Watch in 2018

Who’s funding the biotech industry in Europe? I’ve gathered a list of some of the most active European biotech venture capital firms that will be setting the pace of the industry this year. Biotech can do great things, from curing ... This awesome article The 10 Biotech Venture Capital Firms in Europe to Watch in 2018 appeared first on Labiotech.eu. Be kind and don't copy it without as...


New Venture Fund Closes $102M to Boost Biotech and Medical Device Development

Truffle Capital has raised $102M (€85M), which will be used to support biotech and medical device companies that have the potential to become market leaders. Truffle Capital, founded in 2001 and based in Paris, is a venture capital firm that ... This awesome article New Venture Fund Closes $102M to Boost Biotech and Medical Device Development appeared first on Labiotech.eu. Be kind and don't cop...

AstraZeneca to spin out biotech company focused on autoimmune diseases

AstraZenica has announced that MedImmune, its biologics research and development arm, will spin out a new, independent biotech company named Viela Bio, which will focus on developing medicines for severe autoimmune diseases, according to a press release.The new company will start with three clinical and three preclinical potential new medicines — all molecules from MedImmune’s early-stage infl...


Acticor Biotech Announces the Closing of a 1.7 Million Equity Financing Led by Primer Capital

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the closing of an equity financing led by Primer Capital. The financing round includes investments in equity from Primer Capital and historical shareholders - Anaxago, CapDecisif Management - and private...

Sartorius Stedim Biotech SA: Disclosure of Share Capital and Voting Rights

Dow Jones received a payment from EQS/DGAP to publish this press release. Sartorius Stedim Biotech SA: Disclosure of Share Capital and Voting Rights 04-Dec-2017 / 08:45 CET/CEST Dissemination of a...

Three Ways Venture Capital Firms Maximize Their Biotech Investments

ArticleThree major trends have emerged from the involvement of VC firms in early biotech development: early investment in biotech companies, leveraging big data, and mitigating regulatory risks.

Beck Capital Management LLC Boosts Stake in SPDR S&P Biotech Etf

Beck Capital Management LLC grew its stake in shares of SPDR S&P Biotech ETF by 235.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,899 shares of the exchange traded fund's stock after acquiring an additional 44,866 shares during the period.

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - last conversion of Bracknor financing programme

FIT Biotech Oy Company release February 26, 2018 at 5:30 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - last conversion of Bracknor financing programme Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company'...

Correction to company release dated January 26, 2018 - Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - number of shares

FIT Biotech Oy Company release January 29, 2018 at 11:35 AM EET Correction to company release dated January 26, 2018 - Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - number of shares Due to the conversion of the Convertible Capital Notes, the Company transfers 20,000,000 K shares owned by the Company to ABO.  On company release January 26, 2018, the...

China commits US$1.3b in venture funds for British biotech firms

Future Planet Capital and Eight Great Technologies will invest the funds in Britain's most innovative biotech, medicine and life sciences companies China's increasing zeal for improving biotechnology and medical services is music to the ears of the British government after two venture capital firms received 8 billion yuan in funding commitments from mainland investors during Prime Minister...

Orchard Therapeutics Scoops Up $110M in Funding Round

Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund.

Flagship Pioneering Announces Capital Raise of $618M

NewsThe addition to Flagship's capital base comes on the heels of a year of record growth for the firm and its portfolio companies.Contributed Author:&nb

Orchard Therapeutics Scoops Up $110M in Funding to Advance "Bubble Boy Syndrome" Gene Therapy

Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund.

VCs Are Pouring Billions into Biotech in 2018

While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.

STAT Plus: 3 women in biotech finance to watch in 2018

Meet three women who have pushed to diversify the clubby venture capital world of Silicon Valley and are fighting to advance more women's careers in biotech and health care.

Crowdsource Funding to Launch a Biotech: Is it as Crazy as it Sounds?

The typical way for a biotech to launch is for a scientist, often academia-based, to have come up with a discovery that shows commercial promise—sometimes rather far down the line. Venture capital (VC) firms are on the alert for this type of thing (and vice versa).

Acticor Biotech Announces the Closing of a €1.7 Million Equity Financing Led by Primer Capital

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the closing of an equity financing led by Primer Capital. The financing round includes investments in equity from Primer Capital and historical shareholders - An...

RBC Capital belässt Morphosys auf 'Underperform' - Ziel 57 Euro

Das Analysehaus RBC Capital hat die Einstufung für Morphosys nach Jahreszahlen auf "Underperform" mit einem Kursziel von 57 Euro belassen. Die Kennziffern des Biotech-Unternehmens hätten den Konse...

Engine Biosciences Lands $10M for AI-Driven Drug Discovery Platform

Engine Biosciences(“Engine”), a San Francisco, CA-based biotech company pioneering its artificial intelligence and genomics network biomedicine platform for drug discovery has raised $10 million. The seed round was co-led by by DHVC (Danhua Capital) and 6 Dimensions Capital, with participation from global biopharmaceutical leader WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI ...

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

Dow Jones received a payment from EQS/DGAP to publish this press release. Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL 0...

ASIT biotech Successfully Completes the First Tranche of Its Capital Increase and Raises €9.4 Million

Regulatory News: ASIT biotech (Euronext: ASIT BE0974289218) (BSE:ASIT), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of brea...

Swiss VC Closes €86M Fund for Medical Biotech in Europe

BioMedPartners has raised CHF100M (€86M) that will be invested in medical biotech companies in Switzerland, Germany, and other EU countries. Swiss VC BioMedPartners has managed to gather some big European investors to close its third venture capital fund, called BioMedInvest ... This awesome article Swiss VC Closes €86M Fund for Medical Biotech in Europe appeared first on Labiotech.eu. Be kind...

DowDuPont™ Recommends Rejection of TRC Capital’s “Mini-Tender” Offer

MIDLAND, Mich. & WILMINGTON, Del.–(BUSINESS WIRE)–DowDuPont™ (NYSE:DWDP) today announced that it has been notified of an unsolicited “mini-tender” offer by TRC Capital Corporation to purchase up to 2 million shares, or approximately 0.09 percent of outstanding shares, of DowDuPont Inc.’s … Continue reading → Cet article DowDuPont™ Recommends Rej...

Sansure Biotech Raises $77 Million in Funding Led by Lilly Asia

Sansure Biotech of Changsha, a molecular diagnostics company, raised $77 Million in a funding round led by Lilly Asia Ventures and Highlight Capital with participation from June Capital. Sansure provides innovative molecular diagnosis and genetic testing kits and tools to diagnostic labs and researchers. It makes nucleic acid extraction kits, real time polymerase chain reaction (PCR) diagnostic an...

Hookipa Biotech Raises $60M in Oversubscribed Round C Financing

NewsAll current Hookipa investors, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners participated in the round.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks